DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020
Patrick Jedlowski, Mahdieh F. Jedlowski, Maryam T. Fazel
Topics & Concepts
Adverse Event Reporting SystemMedicinePharmacovigilanceAlogliptinSaxagliptinVildagliptinBullous pemphigoidAdverse effectLinagliptinOdds ratioPharmacoepidemiologyInternal medicineDipeptidyl peptidase-4Diabetes mellitusPharmacologySitagliptinMetforminType 2 diabetesMedical prescriptionImmunologyInsulinEndocrinologyAntibodyAutoimmune Bullous Skin DiseasesPharmacovigilance and Adverse Drug ReactionsDiabetes Treatment and Management